Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key

Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key

Source: 
Fierce Biotech
snippet: 

Gilead Sciences is eagerly awaiting phase 3 data for its rheumatoid arthritis drug filgotinib in the next few weeks that could be an antidote for the biotech’s hepatitis C hangover.